Search Results - "Komrokji, R"

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes by Sallman, D A, Komrokji, R, Vaupel, C, Cluzeau, T, Geyer, S M, McGraw, K L, Al Ali, N H, Lancet, J, McGinniss, M J, Nahas, S, Smith, A E, Kulasekararaj, A, Mufti, G, List, A, Hall, J, Padron, E

“…Although next-generation sequencing has allowed for the detection of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant…”
Get full text

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis by Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, Vannucchi, A M

“…Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET…”
Get full text

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS by Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.

“…In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related…”
Get full text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients by Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, Vannucchi, A M

Get full text

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858 by Eksioglu, E A, Chen, X, Heider, K-H, Rueter, B, McGraw, K L, Basiorka, A A, Wei, M, Burnette, A, Cheng, P, Lancet, J, Komrokji, R, Djeu, J, List, A, Wei, S

“…We recently reported that the accumulation of myeloid-derived suppressor cells (MDSC), defined as CD33 + HLA-DR − Lin − , has a direct role in the pathogenesis…”
Get full text

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes by Komrokji, R.S., List, A.F.

“…The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of…”
Get full text

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium by Zeidan, A M, Al Ali, N, Barnard, J, Padron, E, Lancet, J E, Sekeres, M A, Steensma, D P, DeZern, A, Roboz, G, Jabbour, E, Garcia-Manero, G, List, A, Komrokji, R

“…While therapy-related (t)-myelodysplastic syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS…”
Get full text

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides by Zeidan, A M, Sekeres, M A, Garcia-Manero, G, Steensma, D P, Zell, K, Barnard, J, Ali, N A, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, S D, Maciejewski, J P, List, A, Komrokji, R

“…Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are…”
Get full text

Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’ by Sallman, D A, Komrokji, R, List, A, Padron, E

Get full text

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies by Padron, E, Garcia-Manero, G, Patnaik, M M, Itzykson, R, Lasho, T, Nazha, A, Rampal, R K, Sanchez, M E, Jabbour, E, Al Ali, N H, Thompson, Z, Colla, S, Fenaux, P, Kantarjian, H M, Killick, S, Sekeres, M A, List, A F, Onida, F, Komrokji, R S, Tefferi, A, Solary, E

“…Since its reclassification as a distinct disease entity, clinical research efforts have attempted to establish baseline characteristics and prognostic scoring…”
Get full text

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse? by Zeidan, A M, Sekeres, M A, Barnard, J, Steensma, D P, Komrokji, R

Get full text

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion by Wei, S, Chen, X, McGraw, K, Zhang, L, Komrokji, R, Clark, J, Caceres, G, Billingsley, D, Sokol, L, Lancet, J, Fortenbery, N, Zhou, J, Eksioglu, E A, Sallman, D, Wang, H, Epling-Burnette, P K, Djeu, J, Sekeres, M, Maciejewski, J P, List, A

“…Allelic deletion of the RPS14 gene is a key effector of the hypoplastic anemia in patients with myelodysplastic syndrome (MDS) and chromosome 5q deletion…”
Get full text

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia by Zhang, Q, Ball, M C, Zhao, Y, Balasis, M, Letson, C, Vedder, A, List, A F, Epling-Burnette, P K, Komrokji, R S, Padron, E

“…The interplay between tumor heterogeneity and microenvironmental factors is a critical mechanism for clonal selection in leukemia. Evidence of unique clonal…”
Get full text

Maintenance Therapy with 5-Azacytidine after Allogeneic Hematopoietic Stem Cell Transplant for Myelodysplastic Syndrome Improves Survival by Mishra, A, Al Ali, N, Komrokji, R

Get full text

Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome by Nishihori, T, Komrokji, R, Shain, K, Anasetti, C

Get full text

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL by Garcia-Manero, G., Platzbecker, U., Santini, V., Zeidan, A., Fenaux, P., Komrokji, R., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I.S., Lin, C.-C., Li, J., Zhang, J., Giuseppi, A.C., Kreitz, S., Pozharskaya, V., Keeperman, K., Rose, S., Prebet, T., Degulys, A., Paolini, S., Cluzeau, T., Porta, M. Della

“…We report the full analysis of the COMMANDS trial assessing efficacy and safety of luspatercept versus epoetin alfa (EA) in ESA-naive patients with LR-MDS. 363…”
Get full text

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome by Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E

“…In patients with chronic myelomonocytic leukemia (CMML), age>65 years is an adverse prognostic factor. Our objective in the current study was to examine risk…”
Get full text

P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML by Aguirre, L. E., Ball, S., Jain, A., Al Ali, N., Sallman, D., Kuykendall, A., Sweet, K., Lancet, J., Padron, E., Komrokji, R.

Get full text

P1073: MUTATIONAL LANDSCAPE AND CLINICAL OUTCOMES OF PATIENTS WITH MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA (MLN‐EOS) AND ABNORMALITIES OF PDGFRA, PDGFRB, FGFR1, FLT3 AND JAK REARRANGEMENT by Zhang, Y., Nguyen, L., Lu, C., Wang, E., Lauw, M., Ball, S., Dong, N., Moscinski, L., Chan, O., Yun, S., Sallman, D., Sokol, L., Shah, B., Lancet, J., Komrokji, R., Kuykendall, A., Padron, E., Zhang, L.

Get full text

Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature by Nishihori, T, El-Asmar, J, Shah, B, Hussaini, M, Komrokji, R, List, A, Anasetti, C, Kharfan-Dabaja, M A

Get full text